FDA Broadens Clearance for Agendia's MammaPrint(R)
Huntington Beach, California and Amsterdam (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, announced today that the US Food and Drug Administration (FDA) cleared its MammaPrint breast cancer recurrence test for all ages. MammaPrint is the only FDA-cleared breast cancer recurrence test available to patients and physicians. Over the past three years, the FDA has issued four clearances for ...